Ardelyx Inc.

Company Overview

Business Model: Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines addressing significant unmet medical needs. The company's primary revenue generation mechanisms include product sales of IBSRELA and XPHOZAH, both derived from tenapanor, a minimally absorbed, first-in-class, oral, small molecule sodium/hydrogen exchanger (NHE3) inhibitor. Additionally, Ardelyx, Inc. generates revenue through collaboration partnerships, including licensing fees, milestone payments, product supply, and royalties.

Market Position:

• IBSRELA: Approved in the U.S. for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). Ardelyx, Inc. estimates IBSRELA can benefit approximately 13 million Americans suffering from IBS-C symptoms, many of whom experience inadequate response to other therapies. Competition includes branded products Linzess (linaclotide) and Trulance (plecanatide), as well as generic lubiprostone.
• XPHOZAH: Approved in the U.S. to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy for patients with an inadequate response to or intolerance of phosphate binders. This addresses hyperphosphatemia in over 550,000 adult CKD patients on dialysis in the U.S., with approximately 80% receiving phosphate-lowering therapies and 70% unable to consistently maintain target serum phosphorus levels with phosphate binders alone. XPHOZAH is the first therapy for phosphate management that blocks phosphate absorption at the primary site of uptake. Competition includes various phosphate binders such as Calcium acetate, Lanthanum carbonate, Sevelamer hydrochloride, Sevelamer carbonate, Sucroferric oxyhydroxide, Ferric citrate, and over-the-counter calcium carbonate.

Recent Strategic Developments:

• IBSRELA Label Expansion: In January 2026, Ardelyx, Inc. initiated ACCEL (ten-03-301), a Phase 3 clinical trial to assess the safety and efficacy of tenapanor for the treatment of chronic idiopathic constipation (CIC), a condition estimated to affect over 34 million Americans. Topline data is expected in the second half of 2027.
• Next-Generation NHE3 Inhibitor: In October 2025, the company announced a development program for RDX10531, a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas. An Investigational New Drug (IND) submission to the FDA is planned for the second half of 2026.
• XPHOZAH China Approval: In February 2025, Ardelyx, Inc. announced the National Medical Products Administration (NMPA) of China's Center for Drug Evaluation approved the New Drug Application (NDA) for tenapanor for the control of hyperphosphatemia in adult CKD patients undergoing hemodialysis. This approval triggered a $5.0 million milestone payment to Ardelyx, Inc.
• XPHOZAH Japan Launch: Kyowa Kirin Co., Ltd. launched tenapanor, marketed as PHOZEVEL, in Japan in February 2024 for CKD patients with hyperphosphatemia.
• Patent Issuance: On January 22, 2026, U.S. Patent No. 12,539,299 was issued, relating to the formulation of tenapanor and covering the commercial formulations of IBSRELA and XPHOZAH, with an expiration date of November 26, 2042.

Geographic Footprint:

• Primary Operational Regions: United States, where Ardelyx, Inc. directly commercializes IBSRELA and XPHOZAH.
• International Exposure: Through collaboration agreements, tenapanor is being developed and commercialized in:
  • Canada: Knight Therapeutics, Inc. for hyperphosphatemia and IBS-C (IBSRELA launched March 2021).
  • Japan: Kyowa Kirin Co., Ltd. for cardiorenal indications (PHOZEVEL launched February 2024 for hyperphosphatemia in CKD patients).
  • China: Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. for hyperphosphatemia and IBS-C (NDA approved February 2025 for hyperphosphatemia in CKD patients on hemodialysis).

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 90.3%
• Operating Margin: -10.1%
• Net Margin: -15.1%

Investment in Growth:

• R&D Expenditure: $71.5 million (17.6% of revenue)
• Capital Expenditures: $1.5 million
• Strategic Investments: Ardelyx, Inc. is investing in a Phase 3 clinical trial for tenapanor in chronic idiopathic constipation (CIC) and a development program for RDX10531, a next-generation NHE3 inhibitor.

Business Segment Analysis

Ardelyx, Inc. operates in a single reportable segment focused on the development and commercialization of biopharmaceutical products.

IBSRELA

Financial Performance:

• Revenue: $274.2 million (+73% YoY)
• Operating Margin: Not segment-specific; overall company operating margin is -10.1%.
• Key Growth Drivers: The increase in product sales in 2025 and 2024 primarily reflected higher demand, driven by continued increase in awareness and prescriber experience. To a lesser extent, the increase in 2025 also reflected a higher net price.

Product Portfolio:

• IBSRELA (tenapanor) is approved in the U.S. for the treatment of adults with irritable bowel syndrome with constipation (IBS-C).
• A Phase 3 clinical trial (ACCEL, ten-03-301) was initiated in January 2026 to assess tenapanor for the treatment of chronic idiopathic constipation (CIC), with topline data expected in the second half of 2027.

Market Dynamics:

• The IBS-C market is characterized by an established patient base (approximately 13 million Americans), a limited number of competitors (Linzess, Trulance, generic lubiprostone) all with a single mechanism of action (secretagogues), concentrated prescribers, and a recognized unmet need.
• Ardelyx, Inc. employs a targeted promotional focus on high-writing healthcare providers, supported by omnichannel digital initiatives and patient services programs like ArdelyxAssist.

XPHOZAH

Financial Performance:

• Revenue: $103.6 million (-36% YoY)
• Operating Margin: Not segment-specific; overall company operating margin is -10.1%.
• Key Growth Drivers: The decrease in XPHOZAH product sales in 2025 primarily reflected lower demand and lower net price, both driven by the loss of Medicare Part D reimbursement. This was due to XPHOZAH becoming part of the End-Stage Renal Disease Prospective Payment System (ESRD PPS) on January 1, 2025. This decrease was partially offset by continued growth in other channels and an increased number of patients on treatment compared to 2024.

Product Portfolio:

• XPHOZAH (tenapanor) is approved in the U.S. to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Market Dynamics:

• The hyperphosphatemia market for CKD patients on dialysis reflects an established patient base (over 550,000 adult patients in the U.S.), limited competitors (phosphate binders), concentrated prescribers, and significant unmet need.
• On January 1, 2025, XPHOZAH transitioned into the ESRD PPS, eliminating Medicare Part D coverage for Medicare beneficiaries. This change had a negative and material impact on 2025 XPHOZAH revenue and is expected to result in a materially lower pace of revenue growth compared to expectations before the transition.
• Ardelyx, Inc.'s strategy for XPHOZAH remains a targeted promotional focus on nephrology healthcare providers to preserve patient access regardless of insurance coverage.
• Competition includes various types of phosphate binders, both branded and generic, and several phosphate binders are currently in development by other companies.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: Not disclosed.
• Dividend Payments: Ardelyx, Inc. has never declared or paid cash dividends on its capital stock and currently intends to retain any future earnings to finance the growth and development of its business.
• Dividend Yield: Not applicable.
• Future Capital Return Commitments: Not disclosed.

Balance Sheet Position:

• Cash and Equivalents: $68.0 million (2025), $64.9 million (2024)
• Total Debt: $202.8 million (2025), $150.9 million (2024)
• Net Cash Position: $61.9 million (2025), $99.2 million (2024) (calculated as Cash, Cash Equivalents and Short-term Investments minus Total Debt)
• Credit Rating: Not disclosed.
• Debt Maturity Profile: The total future payment obligation related to the outstanding balance of term loans, excluding interest payments, was $209.9 million as of December 31, 2025, due on July 1, 2028. Ardelyx, Inc. has the option to draw an additional $100.0 million in committed senior secured term loans (Term F and Term G Loans), each for $50.0 million, by June 30, 2026, and December 20, 2026, respectively. These incremental loans would have a maturity date of July 1, 2030.

Cash Flow Generation:

• Operating Cash Flow: $(42.5) million (2025), $(44.8) million (2024)
• Free Cash Flow: $(44.0) million (2025), $(45.8) million (2024) (calculated as Operating Cash Flow minus Purchases of Property and Equipment)
• Cash Conversion Metrics: Not explicitly detailed in the filing.

Operational Excellence

Production & Service Model: Ardelyx, Inc. relies entirely on third-party Contract Manufacturing Organizations (CMOs) for the manufacture of both the Active Pharmaceutical Ingredient (API) and final drug product dosage forms for its commercial products, IBSRELA and XPHOZAH, as well as for clinical trial materials. The company expects to continue this reliance. Ardelyx, Inc. also supplies IBSRELA drug product packaged for the Canadian market to Knight Therapeutics, Inc. and tenapanor drug substance to Kyowa Kirin Co., Ltd. for their commercial needs in Japan.

Supply Chain Architecture: Key Suppliers & Partners:

• CMOs: Third-party CMOs, including certain single-source suppliers, are critical for the production of drug supply.
• Raw Materials: Raw materials necessary for API production are acquired from a limited number of sources.
• Collaboration Partners: Knight Therapeutics, Inc., Kyowa Kirin Co., Ltd., and Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. are supplied with product or drug substance.

Facility Network:

• Manufacturing: Ardelyx, Inc. does not own or operate manufacturing facilities, relying on third-party CMOs.
• Research & Development: Not explicitly detailed in terms of dedicated facilities.
• Distribution: Not explicitly detailed, but products are sold to wholesalers, Group Purchasing Organizations (GPOs), specialty pharmacies, and directly to retailers, hospitals, clinics, and government agencies.

Operational Metrics: Not explicitly disclosed in the filing.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: Ardelyx, Inc. employs a highly experienced specialty sales force with existing relationships across gastrointestinal and nephrology target bases.
• Channel Partners: Products are primarily sold to wholesalers, GPOs, and specialty pharmacies, and to a lesser extent, directly to retailers, hospitals, clinics, and government agencies.
• Digital Platforms: Utilizes innovative omnichannel digital initiatives.

Customer Portfolio: Enterprise Customers:

• Tier 1 Clients (based on 2025 gross product sales):
  • BioRidge Pharma, LLC: 65.9%
  • Cardinal Health: 21.4%
  • McKesson Corporation: 17.9%
  • Cencora (formerly AmerisourceBergen Drug Corporation): 17.3%
• Strategic Partnerships: Ardelyx, Inc. has collaboration agreements with Knight Therapeutics, Inc., Kyowa Kirin Co., Ltd., Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., and METiS Therapeutics Inc.
• Customer Concentration: Ardelyx, Inc. exhibits significant customer concentration with its top wholesalers.

Geographic Revenue Distribution:

• United States: 92.8% of total revenue (from sales of IBSRELA and XPHOZAH).
• Asia Pacific: 5.9% of total revenue (from agreements with Kyowa Kirin Co., Ltd. and Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.).
• North America (Canada): 0.1% of total revenue (from agreement with Knight Therapeutics, Inc.).

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The biotechnology and pharmaceutical industries are highly competitive, with significant competition from companies researching and marketing products for similar diseases. Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• IBSRELA (IBS-C):
  • Linzess (linaclotide)
  • Trulance (plecanatide)
  • Generic lubiprostone
  • Over-the-counter calcium carbonate and other products used for constipation.
• XPHOZAH (Hyperphosphatemia in CKD on Dialysis):
  • Calcium acetate (PhosLo, Phoslyra)
  • Lanthanum carbonate (Fosrenol)
  • Sevelamer hydrochloride (Renagel)
  • Sevelamer carbonate (Renvela)
  • Sucroferric oxyhydroxide (Velphoro)
  • Ferric citrate (Auryxia)
  • Over-the-counter calcium carbonate (Tums, Caltrate).

Emerging Competitive Threats:

• XPHOZAH: At least four phosphate binders are in development, including AP-301 (Alebund Pharmaceutical (Hong Kong) Limited, Phase 3), VS-505 (Vidasym, clinical development), TS-172 (Taisho Pharmaceutical, Phase 3), and OLC (Unicycive Therapeutics, NDA resubmitted). Alebund Pharmaceutical (Hong Kong) Limited is also developing AP-306, an inhibitor of phosphate transporters.

Competitive Response Strategy: Ardelyx, Inc.'s strategy includes driving significant IBSRELA growth, maintaining XPHOZAH commercial momentum through targeted promotional focus on nephrology healthcare providers to preserve patient access, and advancing and expanding its pipeline with initiatives such as the Phase 3 trial for tenapanor in CIC and the development program for RDX10531.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Product Commercialization Dependence: Ardelyx, Inc. is substantially dependent on the successful commercialization of IBSRELA and XPHOZAH. Maintaining market acceptance, growing market share, and securing adequate coverage and reimbursement are critical.
• XPHOZAH Reimbursement Impact: The inclusion of XPHOZAH in the ESRD PPS on January 1, 2025, eliminated Medicare Part D coverage for Medicare beneficiaries, resulting in a negative and material impact on 2025 XPHOZAH revenue and a materially lower pace of revenue growth compared to prior expectations.
• Competition: Significant competition from existing and developing products in the biotechnology and pharmaceutical industries, with competitors potentially developing or commercializing products faster or more successfully.

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Supplier Dependency: Complete reliance on third-party Contract Manufacturing Organizations (CMOs), including certain single-source suppliers, for manufacturing API and finished drug products. Risks include inability to comply with regulatory requirements, raw material shortages, manufacturing/distribution difficulties, and insufficient capacity.
• Geographic Concentration: Reliance on foreign CMOs and Contract Research Organizations (CROs) exposes Ardelyx, Inc. to U.S. legislation, sanctions, trade restrictions (e.g., U.S. BIOSECURE Act), and foreign regulatory requirements, which could increase costs or reduce supply.
• Capacity Constraints: CMOs' maximum or available manufacturing capacities may be insufficient to meet commercial demand, leading to delays or increased costs. Clinical Trial Risks: Future business prospects depend on successfully developing, gaining regulatory approval for, and commercializing product candidates. Clinical trials are long, expensive, and uncertain, with risks of delays, negative results, safety issues, patient recruitment challenges, and regulatory disagreements. Management & Growth: Potential difficulties in managing current activities and growth given the level of managerial, operational, financial, and other resources. Product Liability: Inherent risk of product liability lawsuits from clinical testing and commercialization, potentially leading to substantial liabilities, limits on commercialization, or reputational damage. Data Privacy & Security: Risks from evolving data protection laws (e.g., HIPAA, California Consumer Privacy Act (CCPA), General Data Protection Regulation (GDPR)), cybersecurity threats (e.g., computer viruses, malware, cyber-attacks), and potential for security breaches, data loss, and regulatory penalties. AI Technologies: The rapidly evolving regulatory framework for Artificial Intelligence (AI) Technologies may limit their use or require changes, increasing costs and posing new cybersecurity risks.

Financial & Regulatory Risks

Market & Financial Risks:

• Historical Losses & Future Profitability: Ardelyx, Inc. has incurred losses since its inception and may not achieve or sustain cash flow positivity.
• Financing Needs: May require additional financing for the foreseeable future to invest in growth and pipeline development.
• Stock Price Volatility: The company's stock price is highly volatile due to various internal and external factors.
• Credit & Liquidity: Operating activities may be restricted by covenants in the 2022 Loan Agreement with SLR Investment Corp. An event of default could require immediate repayment of outstanding indebtedness. Regulatory & Compliance Risks:
• Healthcare Reform: Current and future healthcare reform legislation, regulation, or actions by the current administration (e.g., Affordable Care Act (ACA), Inflation Reduction Act of 2022 (IRA), One Big Beautiful Bill Act, GLOBE, GUARD proposals) may increase commercialization costs, adversely affect pricing, and negatively impact business operations and results.
• Ongoing Regulatory Obligations: Approved products (IBSRELA, XPHOZAH) are subject to extensive and ongoing regulatory requirements (e.g., manufacturing processes, labeling, promotion, reporting, Good Manufacturing Practice (cGMP), Good Clinical Practice (GCP)), with non-compliance potentially leading to sanctions or market withdrawal.
• Promotion & Sales Practices: Failure to comply with FDA and other regulations related to the promotion of products for unapproved uses, other sales practices, or patient assistance programs could result in criminal penalties, substantial fines, or other sanctions.
• Adverse Medical Events: Failure to report adverse medical events as required by regulatory agencies could lead to sanctions.
• Government Price Reporting: Non-compliance with reporting and payment obligations under the Medicaid Drug Rebate Program (MDRP), 340B program, U.S. Department of Veterans Affairs (VA) Federal Supply Schedule (FSS) pricing program, or Tricare Retail Pharmacy program could result in additional reimbursement requirements, penalties, sanctions, and fines.
• Foreign Regulatory Approvals: Failure to obtain regulatory approvals in foreign jurisdictions would prevent international marketing of products.
• Employee Misconduct: Risk of employees, independent contractors, or partners engaging in fraudulent conduct or other illegal activities, including noncompliance with regulatory standards and healthcare fraud and abuse laws.

Geopolitical & External Risks

Geopolitical Exposure:

• Geographic Dependencies: International operations and reliance on foreign CMOs and CROs expose Ardelyx, Inc. to geopolitical risks.
• Trade Relations: Changes in U.S. and international trade policies (e.g., export controls, tariffs, U.S. BIOSECURE Act) may adversely impact business and operating results by increasing costs, affecting demand, or restricting supply. Natural Disasters & Catastrophic Events: Operations may be adversely affected by natural disasters, severe weather, public health emergencies, power outages, cyber or telecommunications disruptions, transportation incidents, or other catastrophic events.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas: Ardelyx, Inc. focuses on the discovery and development of innovative medicines, particularly around its active ingredient tenapanor, a NHE3 inhibitor. The company is also developing a next-generation NHE3 inhibitor. Innovation Pipeline:

• Label Extension for IBSRELA: Initiated a Phase 3 clinical trial (ACCEL, ten-03-301) in January 2026 to evaluate tenapanor for the treatment of chronic idiopathic constipation (CIC), with topline data expected in the second half of 2027.
• RDX10531: Announced a development program in October 2025 for RDX10531, a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas. An IND submission to the FDA is planned for the second half of 2026.

Intellectual Property Portfolio:

• Patent Strategy: Ardelyx, Inc. owns seven issued U.S. patents and multiple foreign patents covering the composition and certain methods of using tenapanor. U.S. patent no. 8,541,448, claiming the composition of matter of tenapanor, was extended under the Hatch-Waxman Act to August 1, 2033. Patents covering the use of tenapanor for controlling serum phosphorus are predicted to expire in April 2034. U.S. Patent No. 12,539,299, covering the commercial formulations of IBSRELA and XPHOZAH, was issued on January 22, 2026, and expires on November 26, 2042.
• Licensing Programs: Ardelyx, Inc. has exclusive license agreements with:
  • Kyowa Kirin Co., Ltd. for tenapanor in Japan for cardiorenal indications.
  • Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. for tenapanor in China for hyperphosphatemia and IBS-C.
  • Knight Therapeutics, Inc. for tenapanor in Canada for hyperphosphatemia and IBS-C.
  • METiS Therapeutics Inc. for a portfolio of TGR5 agonist compounds for all therapeutic areas.
• IP Litigation: Not currently involved in material intellectual property litigation, but acknowledges the inherent risks of third-party claims and challenges to its patents.

Technology Partnerships:

• Strategic Alliances: Collaborations with Kyowa Kirin Co., Ltd., Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., Knight Therapeutics, Inc., and METiS Therapeutics Inc. for the development and commercialization of its compounds in specific territories and therapeutic areas.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: Ardelyx, Inc. recognizes the criticality of recruiting and retaining qualified scientific, sales and marketing, clinical, medical, business development, manufacturing, finance, and administrative personnel. Board Composition: The Board of Directors includes David Mott (Chairman), Robert Bazemore, William Bertrand, Jr., J.D., Muna Bhanji, R.Ph., Onaiza Cadoret-Manier, Merdad Parsey, M.D., Ph.D., and Richard Rodgers. The board considers cybersecurity risk as part of its risk oversight function, delegating oversight to the Audit and Compliance Committee.

Human Capital Strategy

Workforce Composition:

• Total Employees: 489 full-time employees as of December 31, 2025, representing an approximately 24% increase from 2024.
• Geographic Distribution: Not explicitly detailed beyond U.S. operations.
• Skill Mix: 93 employees engaged directly in research, development, and manufacturing; 305 in sales and marketing; and 91 in general and administrative activities.

Talent Management: Acquisition & Retention: Ardelyx, Inc. is committed to attracting, retaining, and developing top talent by fostering a professional, respectful, and collaborative workplace with opportunities for career growth. Retention Metrics: Not explicitly disclosed. Employee Value Proposition: Includes base compensation, annual bonuses, quarterly incentives for field-based teams, stock awards, an Employee Stock Purchase Plan, 401(k) with company match, healthcare and insurance benefits, company-funded health savings accounts, flexible spending accounts, family leave, family care resources, and flexible work schedules. Annual pay equity reviews are conducted.

Diversity & Development:

• Diversity Metrics (as of December 31, 2025):
  • Approximately 63% of the workforce is female.
  • 38% of the executive leadership team is female.
  • 54% of employees in managerial roles are female.
  • 35% of the workforce self-identified as members of underrepresented groups.
  • 37% of employees in managerial roles self-identified as members of underrepresented groups.
• Development Programs: Not explicitly detailed beyond general commitment to employee growth and development.
• Culture & Engagement: Fosters a culture where mutual respect, accountability, integrity, and dignity are core values. The company's core values are Passionate, Fearless, Dedicated, and Inclusive. Hybrid and remote working opportunities are offered.

Environmental & Social Impact

Environmental Commitments: Not explicitly detailed in the filing.

Supply Chain Sustainability: Not explicitly detailed in the filing.

Social Impact Initiatives: Not explicitly detailed in the filing.

Business Cyclicality & Seasonality

Demand Patterns: Not explicitly detailed as cyclical or seasonal in the filing. Economic Sensitivity: Demand for healthcare services and pharmaceuticals can be adversely affected by prevailing economic conditions, including unemployment, underemployment, and the resultant loss of insurance coverage. Industry Cycles: Not explicitly detailed in the filing. Planning & Forecasting: Not explicitly detailed in the filing.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations: Ardelyx, Inc. and its contractors are subject to substantial and burdensome requirements from the FDA and comparable regulatory authorities in state, local, and foreign jurisdictions. These regulations govern all stages of drug development, manufacture, marketing, and distribution, including compliance with the Federal Food, Drug, and Cosmetic Act (FFDCA), Good Laboratory Practice (GLP), Investigational New Drug (IND) application procedures, Good Clinical Practice (GCP), and current Good Manufacturing Practice (cGMP) regulations. Healthcare Fraud & Abuse Laws: The company is subject to various federal and state healthcare fraud and abuse laws, including the Anti-Kickback Statute, the federal False Claims Act, the federal Physician Payments Sunshine Act, and the Health Insurance Portability and Accountability Act (HIPAA). Third-Party Coverage and Reimbursement: Sales of pharmaceutical products are significantly dependent on the availability of coverage and adequate reimbursement by third-party payors (e.g., Medicare, Medicaid, commercial managed care). XPHOZAH's inclusion in the ESRD PPS on January 1, 2025, eliminated Medicare Part D coverage for Medicare beneficiaries, materially impacting revenue. Government Price Reporting: Ardelyx, Inc. participates in the Medicaid Drug Rebate Program (MDRP), the 340B program, the U.S. Department of Veterans Affairs (VA) Federal Supply Schedule (FSS) pricing program, and the Tricare Retail Pharmacy program, which impose reporting and rebate/discount obligations. Data Privacy & Security Laws: Subject to numerous state, federal, and foreign laws and regulations governing the collection, dissemination, use, access to, confidentiality, and security of personal information, including health-related information (e.g., HIPAA, California Consumer Privacy Act (CCPA), European Union General Data Protection Regulation (GDPR)). AI Technologies: The regulatory framework for Artificial Intelligence (AI) Technologies is rapidly evolving, with potential for new laws and regulations that could affect the company's operations.

Trade & Export Controls:

• Export Restrictions: Reliance on foreign CMOs and CROs may subject Ardelyx, Inc. to U.S. legislation, sanctions, trade restrictions (e.g., the U.S. BIOSECURE Act enacted in December 2025), and other foreign regulatory requirements, potentially increasing costs or reducing supply.
• Sanctions Compliance: Not explicitly detailed, but implied by general compliance with trade regulations.

Legal Proceedings:

• Shareholder Derivative Lawsuits: Two shareholder derivative lawsuits (Go v. Raab, et al. and Morris v. Raab, et al.) were consolidated and subsequently dismissed on April 30, 2025.
• CMS Lawsuit (XPHOZAH Reimbursement): On July 17, 2024, Ardelyx, Inc., in partnership with the American Association of Kidney Patients (AAKP) and the National Minority Quality Forum (NMQF), filed a lawsuit against CMS challenging XPHOZAH's inclusion in the ESRD PPS. The U.S. District Court for the District of Columbia granted defendants' motion to dismiss on November 8, 2024. Plaintiffs appealed to the United States Court of Appeals for the District of Columbia Circuit on February 4, 2025, with oral argument held on September 25, 2025.
• Securities Class Action (Yarborough Action): A complaint was filed on August 16, 2024, alleging violations of Sections 10(b) and 20(a) of the Exchange Act related to the company's July 2, 2024, announcement regarding the Transitional Drug Add-on Payment Adjustment (TDAPA) for XPHOZAH. An amended complaint was filed on January 13, 2025. The Court granted defendants' motion to dismiss on December 24, 2025, and plaintiffs appealed to the United States Court of Appeals for the First Circuit on January 21, 2026.
• Shareholder Derivative Complaints: Two derivative complaints were filed on September 6 and 13, 2024, alleging violations of the Exchange Act and breaches of fiduciary duty, which were consolidated and stayed pending resolution of the Yarborough Action.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: -1.7% in 2025, -0.7% in 2024, and -0.8% in 2023. The negative rates are primarily due to net losses and the full valuation allowance against deferred tax assets.
• Geographic Tax Planning: Not explicitly detailed.
• Tax Reform Impact: The One Big Beautiful Bill Act (OBBBA), enacted in July 2025, made permanent certain expired and expiring tax provisions and allowed for an accelerated deduction of unamortized domestic research and development costs. The enactment of the OBBBA did not have a material impact on Ardelyx, Inc.'s financial statements.

Net Operating Loss (NOL) Carryforwards:

• Federal: Approximately $572.8 million, of which $422.7 million can be carried forward indefinitely, and the remainder begins to expire in 2030.
• California: Approximately $101.6 million, beginning to expire in 2030.
• Other State: Approximately $128.6 million, beginning to expire in 2031.

Tax Credit Carryforwards:

• Federal R&D Tax Credits: Approximately $19.5 million, beginning to expire in 2027.
• Foreign Tax Credit Carryforwards: Approximately $2.2 million, beginning to expire in 2027.
• California R&D Tax Credits: Approximately $9.4 million, which do not expire.
• California Minimum Tax Credit Carryovers: Approximately $0.1 million, which do not expire.

Insurance & Risk Transfer

Risk Management Framework: Not explicitly detailed in the filing. Insurance Coverage: Ardelyx, Inc. maintains director and officer liability insurance and product liability insurance. Risk Transfer Mechanisms: Not explicitly detailed in the filing.